Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1991 2
1993 5
1994 3
1995 8
1996 4
1997 1
1998 2
2000 1
2001 4
2002 3
2003 1
2004 1
2006 3
2007 6
2008 4
2009 1
2010 3
2011 1
2012 2
2013 3
2014 3
2015 6
2016 4
2017 3
2018 5
2019 2
2020 5
2021 4
2022 2
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Tutt A, et al. Among authors: gutin a. Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30. Nat Med. 2018. PMID: 29713086 Free PMC article. Clinical Trial.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC. Hodgson DR, et al. Among authors: gutin a. Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24. Br J Cancer. 2018. PMID: 30353044 Free PMC article. Clinical Trial.
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Telli ML, et al. Among authors: gutin a. Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8. Clin Cancer Res. 2016. PMID: 26957554 Free PMC article. Clinical Trial.
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Abkevich V, et al. Among authors: gutin a. Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9. Br J Cancer. 2012. PMID: 23047548 Free PMC article.
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS. Timms KM, et al. Among authors: gutin a. Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x. Breast Cancer Res. 2014. PMID: 25475740 Free PMC article.
A new approach to the design of stable proteins.
Shakhnovich EI, Gutin AM. Shakhnovich EI, et al. Among authors: gutin am. Protein Eng. 1993 Nov;6(8):793-800. doi: 10.1093/protein/6.8.793. Protein Eng. 1993. PMID: 8309926
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.
Clarke LE, Warf MB, Flake DD 2nd, Hartman AR, Tahan S, Shea CR, Gerami P, Messina J, Florell SR, Wenstrup RJ, Rushton K, Roundy KM, Rock C, Roa B, Kolquist KA, Gutin A, Billings S, Leachman S. Clarke LE, et al. Among authors: gutin a. J Cutan Pathol. 2015 Apr;42(4):244-52. doi: 10.1111/cup.12475. Epub 2015 Apr 13. J Cutan Pathol. 2015. PMID: 25727210 Free PMC article.
TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition.
Stone S, Abkevich V, Russell DL, Riley R, Timms K, Tran T, Trem D, Frank D, Jammulapati S, Neff CD, Iliev D, Gress R, He G, Frech GC, Adams TD, Skolnick MH, Lanchbury JS, Gutin A, Hunt SC, Shattuck D. Stone S, et al. Among authors: gutin a. Hum Mol Genet. 2006 Sep 15;15(18):2709-20. doi: 10.1093/hmg/ddl204. Epub 2006 Aug 7. Hum Mol Genet. 2006. PMID: 16893906
Computer simulations of prebiotic evolution.
Abkevich VI, Gutin AM, Shakhnovich EI. Abkevich VI, et al. Among authors: gutin am. Pac Symp Biocomput. 1997:27-38. Pac Symp Biocomput. 1997. PMID: 9390277 Free article.
Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk.
Hughes E, Tshiaba P, Gallagher S, Wagner S, Judkins T, Roa B, Rosenthal E, Domchek S, Garber J, Lancaster J, Weitzel J, Kurian AW, Lanchbury JS, Gutin A, Robson M. Hughes E, et al. Among authors: gutin a. JCO Precis Oncol. 2020 Jun 8;4:PO.19.00360. doi: 10.1200/PO.19.00360. eCollection 2020. JCO Precis Oncol. 2020. PMID: 32923876 Free PMC article.
91 results